このアイテムのアクセス数: 9

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
cas.14887.pdf3.34 MBAdobe PDF見る/開く
タイトル: Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy
著者: Bai, Dan
Feng, Huhu
Yang, Jiajun
Yin, Aiping
Qian, Airong
Sugiyama, Hiroshi  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0001-8923-5946 (unconfirmed)
著者名の別形: 杉山, 弘
キーワード: elastomers
fracture toughness
octuple hydrogen bonding
stiffness
toughening mechanisms
発行日: Jun-2021
出版者: Wiley
誌名: Cancer Science
巻: 112
号: 6
開始ページ: 2126
終了ページ: 2139
抄録: The tumor microenvironment, comprised of tumor cells and tumor-infiltrating immune cells, is closely associated with the clinical outcome of clear cell renal cell carcinoma (ccRCC) patients. However, the landscape of immune infiltration in ccRCC has not been fully elucidated. Herein, we applied multiple computational methods and various datasets to reveal the immune infiltrative landscape of ccRCC patients. The tumor immune infiltration (TII) levels of 525 ccRCC patients using a single-sample gene were examined and further categorized into immune infiltration subgroups. The TII score was characterized by distinct clinical traits and showed a significant divergence based on gender, grade, and stage. A high TII score was associated with the ERBB signaling pathway, the TGF-β signaling pathway, and the MTOR signaling pathway, as well as a better prognosis. Furthermore, patients with high TII scores exhibited greater sensitivity to pazopanib. The low TII score was characterized by a high immune infiltration level of CD8⁺ T cells, T follicular helper cells, and regulatory T cells (Tregs). Moreover, the immune check point genes, including CTLA-4, LAG3, PD-1, and IDO1, presented a high expression level in the low TII score group. Patients in the high TII score group demonstrated significant therapeutic advantages and clinical benefits. The findings in this study have the potential to assist in the strategic design of immunotherapeutic treatments for ccRCC.
著作権等: © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
URI: http://hdl.handle.net/2433/293466
DOI(出版社版): 10.1111/cas.14887
PubMed ID: 33735492
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons